Skip to main content
. 2015 Oct 12;6(35):37965–37978. doi: 10.18632/oncotarget.5700

Figure 8. Illustration of lapatinib-enhanced aggressiveness via Raf-1/MAPK-dependent IL-6 expression.

Figure 8

Long-term treatment with lapatinib activates Raf-1/MAPK signaling pathways though downregulation of miR-7 expression. Then, the activated MAPKs induce expression and binding of c-Jun to IL-6 promoter, which leads to the production of IL-6. The secreted IL-6 in turn enhances the migration ability of TNBC cells.